SG11201706236SA - Methods for enhancing efficacy of therapeutic immune cells - Google Patents

Methods for enhancing efficacy of therapeutic immune cells

Info

Publication number: SG11201706236SA
Authority: SG; Singapore
Prior art keywords: methods; immune cells; therapeutic immune; enhancing efficacy; efficacy
Prior art date: 2015-02-06

Application number

SG11201706236SA

Inventor

Dario Campana

Takahiro Kamiya

Original Assignee

Nat Univ Singapore

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-06

Filing date

2016-02-05

Publication date

2017-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706236S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-02-05 Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore

2017-08-30 Publication of SG11201706236SA publication Critical patent/SG11201706236SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Oncology (AREA)
Mycology (AREA)

SG11201706236SA 2015-02-06 2016-02-05 Methods for enhancing efficacy of therapeutic immune cells SG11201706236SA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562112765P	2015-02-06	2015-02-06
US201562130970P	2015-03-10	2015-03-10
PCT/SG2016/050063 WO2016126213A1 (en)	2015-02-06	2016-02-05	Methods for enhancing efficacy of therapeutic immune cells

Publications (1)

Publication Number	Publication Date
SG11201706236SA true SG11201706236SA (en)	2017-08-30

Family

ID=56564429

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201706236SA SG11201706236SA (en)	2015-02-06	2016-02-05	Methods for enhancing efficacy of therapeutic immune cells
SG10201913124RA SG10201913124RA (en)	2015-02-06	2016-02-05	Methods for enhancing efficacy of therapeutic immune cells

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201913124RA SG10201913124RA (en)	2015-02-06	2016-02-05	Methods for enhancing efficacy of therapeutic immune cells

Country Status (19)

Country	Link
US (5)	US10765699B2 (en)
EP (2)	EP3253865B1 (en)
JP (5)	JP6895380B2 (en)
KR (2)	KR20250022235A (en)
CN (4)	CN113713091A (en)
AU (3)	AU2016216149B2 (en)
CA (1)	CA2975851A1 (en)
DK (1)	DK3253865T3 (en)
ES (1)	ES2926384T3 (en)
HR (1)	HRP20220890T1 (en)
HU (1)	HUE059662T2 (en)
LT (1)	LT3253865T (en)
PL (1)	PL3253865T3 (en)
PT (1)	PT3253865T (en)
RS (1)	RS63574B1 (en)
SG (2)	SG11201706236SA (en)
SI (1)	SI3253865T1 (en)
SM (1)	SMT202200353T1 (en)
WO (1)	WO2016126213A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102211120B1 (en)	2014-05-15	2021-02-03	내셔널 유니버시티 오브 싱가포르	Modified natural killer cells and uses thereof
SG11201706236SA (en) *	2015-02-06	2017-08-30	Nat Univ Singapore	Methods for enhancing efficacy of therapeutic immune cells
CN107249602B (en)	2015-02-27	2021-09-28	美商生物细胞基因治疗有限公司	Chimeric Antigen Receptors (CARs) targeting hematologic malignancies, compositions thereof, and methods of use
CA3024508A1 (en)	2016-05-27	2017-11-30	Agenus Inc.	Anti-tim-3 antibodies and methods of use thereof
WO2018027036A1 (en) *	2016-08-03	2018-02-08	Dipersio John F	Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
WO2018081978A1 (en) *	2016-11-03	2018-05-11	深圳华大基因研究院	Method and system for improving gene editing efficiency
EP3545082A4 (en) *	2016-11-22	2020-07-01	National University of Singapore	BLOCKING THE CD7 EXPRESSION AND CHIMERAL ANTIGENT RECEPTORS FOR THE IMMUNOTHERAPY OF T-CELL MALIGNOMAS
EP3585403A4 (en) *	2017-02-22	2020-12-09	H. Lee Moffitt Cancer Center And Research Institute, Inc.	TIM3 BINDING CHIMERA ANTIGEN RECEPTORS
TW201837175A (en) *	2017-03-13	2018-10-16	美商凱特製藥公司	Chimeric antigen receptor for melanoma and use thereof
KR20240057444A (en)	2017-03-27	2024-05-02	내셔널 유니버시티 오브 싱가포르	Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
US11896616B2 (en)	2017-03-27	2024-02-13	National University Of Singapore	Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN111247241A (en) *	2017-08-10	2020-06-05	新加坡国立大学	T cell receptor-deficient chimeric antigen receptor T cells and methods of use thereof
WO2019077037A1 (en) *	2017-10-18	2019-04-25	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Methods and compounds for improved immune cell therapy
US11912780B2 (en)	2017-10-25	2024-02-27	Actinium Pharmaceuticals, Inc.	Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
JP7372920B2 (en) *	2017-12-29	2023-11-01	セレクティス	Methods for improving the generation of CAR T cells
JP7458993B2 (en) *	2018-01-25	2024-04-01	クリナンミカコーポレイション	MICA/B antibody and usage
CN108314739B (en) *	2018-02-05	2020-07-14	深圳市默赛尔生物医学科技发展有限公司	Multi-signal chimeric antigen receptor and its expression gene, its modified NK cells and application
SG11202007156QA (en)	2018-02-09	2020-08-28	Nat Univ Singapore	Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3758755A1 (en) *	2018-02-26	2021-01-06	Ablynx N.V.	Improved nucleotide sequences encoding peptide linkers
SG11202008976YA (en)	2018-04-02	2020-10-29	Nat Univ Singapore	Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3784776A4 (en) *	2018-05-23	2022-01-26	National University of Singapore	BLOCKADE OF CD2 OBR SURFACE EXPRESSION AND EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY OF T-CELL MALIGNOS
US20200054675A1 (en)	2018-06-01	2020-02-20	Washington University	Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy
WO2020044239A1 (en)	2018-08-29	2020-03-05	National University Of Singapore	A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN109207430A (en) *	2018-09-25	2019-01-15	华东师范大学	A kind of Chimeric antigen receptor NK cell and its preparation method and application
CN109266618B (en) *	2018-10-18	2021-04-23	赛元生物科技(杭州)有限公司	Macrophage capable of targeting tumor cells and preparation method thereof
WO2020085827A1 (en) *	2018-10-24	2020-04-30	주식회사 툴젠	Modified immunocytes
ES3035857T3 (en)	2018-11-01	2025-09-10	Gracell Biotechnologies Shanghai Co Ltd	Compositions and methods for t cell engineering
JP2022512994A (en)	2018-11-14	2022-02-07	メディシックスセラピューティクスピーティーイーリミテッド	Two gene vectors that generate CAR-T cells and their use
CN109652379B (en) *	2018-12-29	2022-08-16	博生吉医药科技(苏州)有限公司	CD7 chimeric antigen receptor modified NK-92MI cell and application thereof
CA3131533A1 (en)	2019-03-05	2020-09-10	Nkarta, Inc.	Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
BR112021022682A2 (en)	2019-05-14	2022-02-22	Provention Bio Inc	Methods and compositions for preventing type 1 diabetes
GB201914611D0 (en) *	2019-10-09	2019-11-20	Autolus Ltd	Engineered immune cell
US20240082399A1 (en) *	2019-10-11	2024-03-14	The Board Of Trustees Of The Leland Stanford Junior University	Recombinant polypeptides for regulatable cellular localization
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
CN113005088B (en) *	2019-12-19	2024-06-04	苏州方德门达新药开发有限公司	Engineered T cells, their preparation and use
CN113088495B (en) *	2020-01-09	2024-08-16	苏州方德门达新药开发有限公司	Engineered T cells, their preparation and use
MX2022010685A (en) *	2020-02-27	2022-09-23	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells.
CN113801238A (en) *	2020-06-11	2021-12-17	南京北恒生物科技有限公司	Engineered immune cells expressing NK inhibitory molecules and uses thereof
CA3182445A1 (en)	2020-06-11	2021-12-16	Francisco Leon	Methods and compositions for preventing type 1 diabetes
AU2021294559A1 (en)	2020-06-22	2023-02-23	Ramot At Tel-Aviv University Ltd.	Multi subunit protein modules, cells expressing same and uses thereof
CN112195155A (en) *	2020-08-11	2021-01-08	广东万海细胞生物科技有限公司	A kind of universal CAR-T cell and preparation method thereof
CN120025983A (en) *	2020-11-03	2025-05-23	南京北恒生物科技有限公司	Chimeric antigen receptor targeting CD7 and its use
WO2022104109A1 (en)	2020-11-13	2022-05-19	Catamaran Bio, Inc.	Genetically modified natural killer cells and methods of use thereof
EP4259782A1 (en) *	2020-12-14	2023-10-18	Allogene Therapeutics, Inc.	Methods and reagents for characterizing car t cells for therapies
WO2022133169A1 (en)	2020-12-18	2022-06-23	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
CN115786271B (en) *	2021-01-12	2025-07-22	上海雅科生物科技有限公司	Engineered immune cells targeting CD7, chimeric antigen receptor, CD7 blocking molecule and application
WO2022166365A1 (en) *	2021-02-03	2022-08-11	南京北恒生物科技有限公司	Novel chimeric antigen receptor and use thereof
AU2022237618A1 (en)	2021-03-17	2023-10-12	Create Medicines, Inc.	Engineered chimeric fusion protein compositions and methods of use thereof
JP2024518100A (en)	2021-05-11	2024-04-24	マイエロイド・セラピューティクス，インコーポレーテッド	Methods and compositions for genomic integration
CN113416701B (en) *	2021-07-28	2023-05-09	新疆西部赛澳生物科技有限责任公司	NK cell culture medium and culture method
CN118103392A (en) *	2021-07-30	2024-05-28	羿尊生物医药（浙江）有限公司	Universal T cells and their applications
AU2024207657A1 (en)	2023-01-12	2025-07-24	National University Of Singapore	Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies
WO2024154122A1 (en)	2023-01-18	2024-07-25	Gilboa Therapeutics LTD	Immune cells expressing a complement receptor and uses thereof
WO2024236557A1 (en)	2023-05-12	2024-11-21	Gilboa Therapeutics LTD	Compositions comprising an fc domain for the treatment of medical conditions
CN116731205B (en) *	2023-05-19	2024-02-27	皖南医学院第一附属医院（皖南医学院弋矶山医院）	Immunopotentiating fusion protein for expressing TGF beta RII and TIM3 extracellular region and application thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
CA2018248A1 (en)	1989-06-07	1990-12-07	Clyde W. Shearman	Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1999014353A2 (en)	1997-09-19	1999-03-25	Dana-Farber Cancer Institute, Inc.	Intrabody-mediated control of immune reactions
WO2001029058A1 (en)	1999-10-15	2001-04-26	University Of Massachusetts	Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en)	1999-11-05	2001-12-04	Cambria Biosciences, Llc	Insect control agent
WO2001096584A2 (en)	2000-06-12	2001-12-20	Akkadix Corporation	Materials and methods for the control of nematodes
US6699473B2 (en)	2000-10-13	2004-03-02	Uab Research Foundation	Human anti-epidermal growth factor receptor single-chain antibodies
US7229960B2 (en) *	2000-11-03	2007-06-12	University Of Vermont And State Agricultural College	Methods and compositions for inhibiting GRB7
WO2003051926A2 (en)	2001-12-14	2003-06-26	Friedrich-Alexander-Universitaet Erlangen-Nuernberg	Anti-cd7 immunotoxin as fusion protein
US20090191213A9 (en)	2003-07-02	2009-07-30	Novo Nordisk A/S	Compositions and methods for regulating NK cell activity
KR101325023B1 (en)	2003-07-02	2013-11-04	노보 노르디스크 에이/에스	Compositions and methods for regulating nk cell activity
WO2005017163A2 (en)	2003-08-15	2005-02-24	Imperial College Innovations Limited	Phenotypic knockout of cell-surface proteins
US20130266551A1 (en) *	2003-11-05	2013-10-10	St. Jude Children's Research Hospital, Inc.	Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
AU2004309373A1 (en)	2003-12-22	2005-07-14	Amgen Inc.	Methods for identifying functional antibodies
EP2287195B1 (en)	2004-07-01	2019-05-15	Novo Nordisk A/S	Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
US20060121043A1 (en)	2004-10-27	2006-06-08	Medimmune, Inc.	Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
US20090196850A1 (en)	2005-01-06	2009-08-06	Novo Nordisk A/S	Anti-Kir Combination Treatments and Methods
US20070036773A1 (en) *	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
CA2625998C (en)	2005-10-06	2015-12-01	Xencor, Inc.	Optimized anti-cd30 antibodies
WO2007126782A2 (en) *	2006-03-28	2007-11-08	Hampton University	Hadron treatment planning with adequate biological weighting
CA2676049C (en)	2007-03-01	2018-04-10	Symphogen A/S	Recombinant anti-epidermal growth factor receptor antibody compositions
HRP20130649T1 (en)	2007-09-07	2013-08-31	Agensys, Inc.	Antibodies and related molecules that bind to 24p4c12 proteins
JP5774312B2 (en)	2008-01-24	2015-09-09	ノボ・ノルデイスク・エー／エス	Humanized anti-human NKG2A monoclonal antibody
EP2488867B1 (en)	2009-10-14	2020-09-30	Janssen Biotech, Inc.	Methods of affinity maturing antibodies
US9273283B2 (en) *	2009-10-29	2016-03-01	The Trustees Of Dartmouth College	Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
BR112014020499A2 (en)	2012-02-22	2019-09-24	Univ Pennsylvania	isolated nucleic acid sequence, t-cell, vector, and persistent t-cell population
PT3241902T (en)	2012-05-25	2018-05-28	Univ California	METHODS AND COMPOSITIONS FOR MODIFICATION OF TARGETED TARGET DNA BY RNA AND FOR MODULATION DIRECTED BY TRANSCRIPTION RNA
CA2878928C (en) *	2012-07-13	2023-03-14	The Trustees Of The University Of Pennsylvania	Toxicity management for anti-tumor activity of cars
AU2013329186B2 (en) *	2012-10-10	2019-02-14	Sangamo Therapeutics, Inc.	T cell modifying compounds and uses thereof
US8697359B1 (en)	2012-12-12	2014-04-15	The Broad Institute, Inc.	CRISPR-Cas systems and methods for altering expression of gene products
KR101521224B1 (en)	2012-12-20	2015-05-19	한양대학교 산학협력단	Humanized single chain fragment antibody(scFv) carrier specific for T cell
KR102160322B1 (en) *	2012-12-27	2020-09-25	아두로 바이오테크, 인코포레이티드	Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CA3115383A1 (en) *	2013-02-06	2014-08-14	Celgene Corporation	Modified t lymphocytes having improved specificity
WO2014134165A1 (en)	2013-02-26	2014-09-04	Memorial Sloan-Kettering Cancer Center	Compositions and methods for immunotherapy
SG10201705245TA (en)	2013-03-14	2017-07-28	Macrogenics Inc	Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
EP3004337B1 (en)	2013-05-29	2017-08-02	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015075470A1 (en) *	2013-11-21	2015-05-28	Ucl Business Plc	Cell
PL3105317T3 (en)	2014-02-14	2019-02-28	Cellectis	IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING PRESENT ANTIGENES BOTH ON IMMUNE CELLS AND PATHOLOGICAL CELLS
GB201405845D0 (en)	2014-04-01	2014-05-14	Ucl Business Plc	Signalling system
CA2954414A1 (en)	2014-07-15	2016-01-21	Juno Therapeutics, Inc.	Engineered cells for adoptive cell therapy
KR20170068539A (en) *	2014-10-07	2017-06-19	셀렉티스	Method for modulating car-induced immune cells activity
ES2983094T3 (en)	2014-10-31	2024-10-21	Univ Pennsylvania	Alteration of gene expression in CAR-T cells and their uses
HRP20240357T1 (en)	2014-12-24	2024-06-07	Autolus Limited	Cell
WO2016126608A1 (en) *	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
SG11201706236SA (en)	2015-02-06	2017-08-30	Nat Univ Singapore	Methods for enhancing efficacy of therapeutic immune cells
CN107249602B (en)	2015-02-27	2021-09-28	美商生物细胞基因治疗有限公司	Chimeric Antigen Receptors (CARs) targeting hematologic malignancies, compositions thereof, and methods of use
BR112017018770A2 (en) *	2015-03-02	2018-04-17	Innovative Cellular Therapeutics CO., LTD.	reduced immune tolerance induced by pd-l1
HK1257177A1 (en)	2015-06-19	2019-10-18	麻省理工学院	Tumor immunotherapy
MA42895A (en)	2015-07-15	2018-05-23	Juno Therapeutics Inc	MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
CN108472314A (en)	2015-07-31	2018-08-31	明尼苏达大学董事会	Modified Cells and Therapeutics
BR112018006811A2 (en)	2015-10-06	2018-10-16	Regents Of The University Of Minnesota	therapeutic compounds and methods
US20180371052A1 (en)	2015-12-22	2018-12-27	Icell Gene Therapeutics Llc	Chimeric antigen receptors and enhancement of anti-tumor activity
US11390658B2 (en)	2016-06-06	2022-07-19	St. Jude Children's Research Hospital	Anti-CD7 chimeric antigen receptor and method of use thereof
JP7114490B2 (en)	2016-06-24	2022-08-08	アイセル・ジーン・セラピューティクス・エルエルシー	Construction of chimeric antibody receptors (CARs) and methods of their use
CA2937157A1 (en)	2016-07-25	2018-01-25	Ucl Business Plc	Protein-based t-cell receptor knockdown
WO2018027036A1 (en)	2016-08-03	2018-02-08	Dipersio John F	Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
EP3545082A4 (en)	2016-11-22	2020-07-01	National University of Singapore	BLOCKING THE CD7 EXPRESSION AND CHIMERAL ANTIGENT RECEPTORS FOR THE IMMUNOTHERAPY OF T-CELL MALIGNOMAS
GB201622044D0 (en)	2016-12-22	2017-02-08	Ucl Business Plc	T cell-targeted T cells
AU2018208614A1 (en)	2017-01-10	2019-07-11	The General Hospital Corporation	Modified T cells and methods of their use
CN111247241A (en)	2017-08-10	2020-06-05	新加坡国立大学	T cell receptor-deficient chimeric antigen receptor T cells and methods of use thereof
JP2022512994A (en)	2018-11-14	2022-02-07	メディシックスセラピューティクスピーティーイーリミテッド	Two gene vectors that generate CAR-T cells and their use

2016
- 2016-02-05 SG SG11201706236SA patent/SG11201706236SA/en unknown
- 2016-02-05 JP JP2017541243A patent/JP6895380B2/en active Active
- 2016-02-05 LT LTEPPCT/SG2016/050063T patent/LT3253865T/en unknown
- 2016-02-05 DK DK16746922.0T patent/DK3253865T3/en active
- 2016-02-05 EP EP16746922.0A patent/EP3253865B1/en active Active
- 2016-02-05 WO PCT/SG2016/050063 patent/WO2016126213A1/en not_active Ceased
- 2016-02-05 SM SM20220353T patent/SMT202200353T1/en unknown
- 2016-02-05 HR HRP20220890TT patent/HRP20220890T1/en unknown
- 2016-02-05 SG SG10201913124RA patent/SG10201913124RA/en unknown
- 2016-02-05 US US15/548,577 patent/US10765699B2/en active Active
- 2016-02-05 PL PL16746922.0T patent/PL3253865T3/en unknown
- 2016-02-05 HU HUE16746922A patent/HUE059662T2/en unknown
- 2016-02-05 CN CN202111064400.5A patent/CN113713091A/en active Pending
- 2016-02-05 PT PT167469220T patent/PT3253865T/en unknown
- 2016-02-05 KR KR1020257003185A patent/KR20250022235A/en active Pending
- 2016-02-05 CA CA2975851A patent/CA2975851A1/en active Pending
- 2016-02-05 CN CN202210667502.4A patent/CN115029362A/en active Pending
- 2016-02-05 RS RS20220680A patent/RS63574B1/en unknown
- 2016-02-05 CN CN201680018962.7A patent/CN107709548B/en active Active
- 2016-02-05 KR KR1020177024662A patent/KR102763121B1/en active Active
- 2016-02-05 SI SI201631593T patent/SI3253865T1/en unknown
- 2016-02-05 EP EP22180254.9A patent/EP4134430A1/en active Pending
- 2016-02-05 ES ES16746922T patent/ES2926384T3/en active Active
- 2016-02-05 AU AU2016216149A patent/AU2016216149B2/en active Active
- 2016-02-05 CN CN202210661143.1A patent/CN114891816B/en active Active
2020
- 2020-07-30 US US16/943,400 patent/US12404491B2/en active Active
2021
- 2021-06-07 JP JP2021095192A patent/JP7320560B2/en active Active
2022
- 2022-06-29 AU AU2022204601A patent/AU2022204601B2/en active Active
- 2022-07-12 US US17/862,721 patent/US11679132B2/en active Active
- 2022-07-12 US US17/862,797 patent/US12404492B2/en active Active
2023
- 2023-07-24 JP JP2023119583A patent/JP7717762B2/en active Active
- 2023-07-24 JP JP2023119584A patent/JP7719128B2/en active Active
2025
- 2025-07-03 AU AU2025205077A patent/AU2025205077A1/en active Pending
- 2025-07-24 JP JP2025124172A patent/JP2025169264A/en active Pending
- 2025-07-30 US US19/285,735 patent/US20250354119A1/en active Pending

Also Published As

Publication number	Publication date
EP3253865A1 (en)	2017-12-13
SG10201913124RA (en)	2020-03-30
US12404492B2 (en)	2025-09-02
AU2022204601B2 (en)	2025-04-03
KR20170109052A (en)	2017-09-27
US11679132B2 (en)	2023-06-20
US20250354119A1 (en)	2025-11-20
JP2025169264A (en)	2025-11-12
ES2926384T3 (en)	2022-10-25
AU2025205077A1 (en)	2025-07-24
NZ734107A (en)	2024-12-20
RS63574B1 (en)	2022-10-31
AU2022204601A1 (en)	2022-07-21
US20210046112A1 (en)	2021-02-18
JP6895380B2 (en)	2021-06-30
JP7320560B2 (en)	2023-08-03
US12404491B2 (en)	2025-09-02
WO2016126213A1 (en)	2016-08-11
CN107709548B (en)	2022-06-28
PL3253865T3 (en)	2022-10-10
JP7717762B2 (en)	2025-08-04
KR102763121B1 (en)	2025-02-04
EP4134430A1 (en)	2023-02-15
DK3253865T3 (en)	2022-08-15
CN114891816A (en)	2022-08-12
CN113713091A (en)	2021-11-30
SMT202200353T1 (en)	2022-09-14
CN114891816B (en)	2025-01-21
US10765699B2 (en)	2020-09-08
JP2023153142A (en)	2023-10-17
SI3253865T1 (en)	2022-10-28
HRP20220890T1 (en)	2022-10-14
US20220370501A1 (en)	2022-11-24
AU2016216149A1 (en)	2017-08-17
LT3253865T (en)	2022-11-10
PT3253865T (en)	2022-10-03
US20220347219A1 (en)	2022-11-03
EP3253865A4 (en)	2018-10-24
KR20250022235A (en)	2025-02-14
JP2023153141A (en)	2023-10-17
CN115029362A (en)	2022-09-09
AU2016216149B2 (en)	2022-03-31
JP2021137024A (en)	2021-09-16
US20180008638A1 (en)	2018-01-11
CA2975851A1 (en)	2016-08-11
CN107709548A (en)	2018-02-16
EP3253865B1 (en)	2022-06-22
JP7719128B2 (en)	2025-08-05
JP2018507685A (en)	2018-03-22
HUE059662T2 (en)	2022-12-28

Publication	Publication Date	Title
SG10201913124RA (en)	2020-03-30	Methods for enhancing efficacy of therapeutic immune cells
IL253803B (en)	2021-06-30	Treatment of hypoparathyroidism
SG11201802794PA (en)	2018-05-30	Therapeutic compounds and methods
PT3132034T (en)	2020-11-12	Therapeutic
GB201512365D0 (en)	2015-08-19	Novel therapy
IL285882A (en)	2021-09-30	Therapeutic uses of l-4-chlorokynurenine
GB201410216D0 (en)	2014-07-23	Therapeutic
GB201416832D0 (en)	2014-11-05	Methods of treatment
IL253847A0 (en)	2017-09-28	Methods of treating diseases
GB201522223D0 (en)	2016-01-27	Therapeutic T cells
GB201516068D0 (en)	2015-10-28	Novel therapy
GB201510637D0 (en)	2015-07-29	Therapeutic
GB201500534D0 (en)	2015-02-25	Sexual stimulator
GB201505382D0 (en)	2015-05-13	Novel therapy
GB201407837D0 (en)	2014-06-18	Methods of cancer therapy
GB201512139D0 (en)	2015-08-19	Methods of treatment
GB201410334D0 (en)	2014-07-23	Therapeutic
GB201518805D0 (en)	2015-12-09	Therapy
GB201506944D0 (en)	2015-06-10	Therapeutic treatment
HUP1500253A2 (en)	2017-03-28	Therapeutic energy disc
GB201512101D0 (en)	2015-08-19	Therapeutic treatments
GB201512103D0 (en)	2015-08-19	Therapeutic treatments
GB201418508D0 (en)	2014-12-03	Therapeutic
GB201413719D0 (en)	2014-09-17	Therapeutic
GB201410832D0 (en)	2014-07-30	Therapeutic